Researchers have identified an enzyme linked to pregnancy-induced hypertension – also known as pre-eclampsia – a pregnancy complication characterized by high blood pressure and swelling due to fluid retention. The findings could be used to better screen for – and treat – this condition.
Pregnancy-induced hypertension, which occurs in approximately 10 percent of pregnancies, is a major cause of maternal and fetal deaths, yet the cause is unknown.
The study, led by researchers in Cleveland Clinic's Lerner Research Institute, examined mice for corin – an enzyme normally present in the heart – and determined that the deficiency of this enzyme in the uterus may be an underlying cause of the disease. The study was published today in Nature.
Pregnancy poses a major challenge for controlling blood pressure. As blood volume increases, maintaining normal blood pressure becomes more difficult. During pregnancy, the narrow, curly uterine arteries are enlarged to thin-walled vessels, an adaptive change important for maintaining normal maternal blood pressure and boosting blood flow to the fetus. However, in pregnant women with hypertension, the changes in uterine arteries become defective.
While this study was initially conducted on mice, the researchers extended their study to patients with pre-eclampsia. The researchers found that many pre-eclamptic patients had low levels of corin in their uterus, and corin gene mutations in pre-eclamptic patients were identified.
"Additional studies on corin or its related molecules may help to develop new methods to diagnose and treat pregnancy-induced hypertension," said Qingyu Wu, M.D., Ph.D., a researcher in the Department of Molecular Cardiology in Cleveland Clinic's Lerner Research Institute and the lead researcher on the study.
In this study, Dr. Wu and his staff collaborated with investigators at the Cyrus Tang Hematology Center of Soochow University in Suzhou, China, and Shanghai Jiaotong University in China, who conducted clinical studies.
About Cleveland ClinicCleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S.News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. About 2,800 full-time salaried physicians and researchers and 11,000 nurses represent 120 medical specialties and subspecialties. Cleveland Clinic Health System includes a main campus near downtown Cleveland, eight community hospitals and 18 Family Health Centers in Northeast Ohio, Cleveland Clinic Florida, the Lou Ruvo Center for Brain Health in Las Vegas, Cleveland Clinic Canada, and opening in 2013, Cleveland Clinic Abu Dhabi. In 2010, there were 4 million visits throughout the Cleveland Clinic health system and 167,000 hospital admissions. Patients came for treatment from every state and from more than 100 countries. Visit us at www.clevelandclinic.org. Follow us at www.twitter.com/ClevelandClinic.
Dan Doron | EurekAlert!
Remdesivir prevents MERS coronavirus disease in monkeys
14.02.2020 | NIH/National Institute of Allergy and Infectious Diseases
Recent advances in addressing tuberculosis give hope for future
12.02.2020 | NIH/National Institute of Allergy and Infectious Diseases
Most natural and artificial surfaces are rough: metals and even glasses that appear smooth to the naked eye can look like jagged mountain ranges under the microscope. There is currently no uniform theory about the origin of this roughness despite it being observed on all scales, from the atomic to the tectonic. Scientists suspect that the rough surface is formed by irreversible plastic deformation that occurs in many processes of mechanical machining of components such as milling.
Prof. Dr. Lars Pastewka from the Simulation group at the Department of Microsystems Engineering at the University of Freiburg and his team have simulated such...
Investigation of the temperature dependence of the skyrmion Hall effect reveals further insights into possible new data storage devices
The joint research project of Johannes Gutenberg University Mainz (JGU) and the Massachusetts Institute of Technology (MIT) that had previously demonstrated...
Researchers at Chalmers University of Technology, Sweden, recently completed a 5-year research project looking at how to make fibre optic communications systems more energy efficient. Among their proposals are smart, error-correcting data chip circuits, which they refined to be 10 times less energy consumptive. The project has yielded several scientific articles, in publications including Nature Communications.
Streaming films and music, scrolling through social media, and using cloud-based storage services are everyday activities now.
After helping develop a new approach for organic synthesis -- carbon-hydrogen functionalization -- scientists at Emory University are now showing how this approach may apply to drug discovery. Nature Catalysis published their most recent work -- a streamlined process for making a three-dimensional scaffold of keen interest to the pharmaceutical industry.
"Our tools open up whole new chemical space for potential drug targets," says Huw Davies, Emory professor of organic chemistry and senior author of the paper.
Superconductivity approaching room temperature may be possible in hydrogen-rich compounds at much lower pressures than previously expected
Reaching room-temperature superconductivity is one of the biggest dreams in physics. Its discovery would bring a technological revolution by providing...
12.02.2020 | Event News
16.01.2020 | Event News
15.01.2020 | Event News
17.02.2020 | Life Sciences
17.02.2020 | Information Technology
17.02.2020 | Life Sciences